blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP1917259

EP1917259 - PYRAZINE KINASE INHIBITORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  30.11.2012
Database last updated on 31.08.2024
Most recent event   Tooltip18.07.2014Lapse of the patent in a contracting state
New state(s): HU
published on 20.08.2014  [2014/34]
Applicant(s)For all designated states
VERTEX PHARMACEUTICALS INCORPORATED
130 Waverly Street
Cambridge, MA 02139 / US
[2008/19]
Inventor(s)01 / MORTIMORE, Michael
Unit 88 Milton Park
Abingdon, Oxfordshire OX14 4RY / GB
02 / GOLEC, Julian, M.C.
Unit 88 Milton Park
Abingdon, Oxfordshire OX14 4RY / GB
 [2008/19]
Representative(s)Coles, Andrea Birgit, et al
Kilburn & Strode LLP
Lacon London
84 Theobalds Road
London WC1X 8NL / GB
[N/P]
Former [2009/39]Coles, Andrea Birgit, et al
Kilburn & Strode LLP 20 Red Lion Street
London WC1R 4PJ / GB
Former [2008/19]Hedley, Nicholas James Matthew, et al
Kilburn & Strode 20 Red Lion Street
London WC1R 4PJ / GB
Application number, filing date06801765.617.08.2006
[2008/19]
WO2006US32191
Priority number, dateUS20050709541P18.08.2005         Original published format: US 709541 P
US20050709760P19.08.2005         Original published format: US 709760 P
US20050720596P26.09.2005         Original published format: US 720596 P
[2008/19]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2007022384
Date:22.02.2007
Language:EN
[2007/08]
Type: A2 Application without search report 
No.:EP1917259
Date:07.05.2008
Language:EN
The application published by WIPO in one of the EPO official languages on 22.02.2007 takes the place of the publication of the European patent application.
[2008/19]
Type: B1 Patent specification 
No.:EP1917259
Date:25.01.2012
Language:EN
[2012/04]
Search report(s)International search report - published on:EP05.04.2007
ClassificationIPC:C07D403/12, C07D417/12, A61K31/497
[2008/19]
CPC:
C07D241/18 (EP,US); A61P11/06 (EP); A61P25/00 (EP);
A61P29/00 (EP); A61P35/00 (EP); A61P35/02 (EP);
A61P37/06 (EP); A61P37/08 (EP); A61P43/00 (EP);
A61P9/00 (EP); C07D403/12 (EP,US); C07D417/12 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2008/19]
TitleGerman:PYRAZINKINASEINHIBITOREN[2008/19]
English:PYRAZINE KINASE INHIBITORS[2008/19]
French:INHIBITEURS DE PYRAZINE KINASES[2008/19]
Entry into regional phase22.02.2008National basic fee paid 
22.02.2008Designation fee(s) paid 
22.02.2008Examination fee paid 
Examination procedure22.02.2008Examination requested  [2008/19]
17.04.2008Amendment by applicant (claims and/or description)
08.07.2009Despatch of a communication from the examining division (Time limit: M06)
14.01.2010Reply to a communication from the examining division
27.07.2011Communication of intention to grant the patent
24.11.2011Fee for grant paid
24.11.2011Fee for publishing/printing paid
16.12.2011Despatch of invitation to pay additional claims fees (Time limit: M02)
17.12.2011Payment of the additional claims fees
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  08.07.2009
Opposition(s)26.10.2012No opposition filed within time limit [2013/01]
Fees paidRenewal fee
25.08.2008Renewal fee patent year 03
25.08.2009Renewal fee patent year 04
25.08.2010Renewal fee patent year 05
25.08.2011Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU17.08.2006
AT25.01.2012
BE25.01.2012
CY25.01.2012
CZ25.01.2012
DK25.01.2012
EE25.01.2012
FI25.01.2012
IT25.01.2012
LT25.01.2012
LV25.01.2012
NL25.01.2012
PL25.01.2012
RO25.01.2012
SE25.01.2012
SI25.01.2012
SK25.01.2012
TR25.01.2012
BG25.04.2012
GR26.04.2012
ES06.05.2012
IS25.05.2012
PT25.05.2012
IE17.08.2012
LU17.08.2012
MC31.08.2012
[2014/34]
Former [2014/27]AT25.01.2012
BE25.01.2012
CY25.01.2012
CZ25.01.2012
DK25.01.2012
EE25.01.2012
FI25.01.2012
IT25.01.2012
LT25.01.2012
LV25.01.2012
NL25.01.2012
PL25.01.2012
RO25.01.2012
SE25.01.2012
SI25.01.2012
SK25.01.2012
TR25.01.2012
BG25.04.2012
GR26.04.2012
ES06.05.2012
IS25.05.2012
PT25.05.2012
IE17.08.2012
LU17.08.2012
MC31.08.2012
Former [2014/21]AT25.01.2012
BE25.01.2012
CY25.01.2012
CZ25.01.2012
DK25.01.2012
EE25.01.2012
FI25.01.2012
IT25.01.2012
LT25.01.2012
LV25.01.2012
NL25.01.2012
PL25.01.2012
RO25.01.2012
SE25.01.2012
SI25.01.2012
SK25.01.2012
TR25.01.2012
BG25.04.2012
GR26.04.2012
ES06.05.2012
IS25.05.2012
PT25.05.2012
IE17.08.2012
MC31.08.2012
Former [2013/33]AT25.01.2012
BE25.01.2012
CY25.01.2012
CZ25.01.2012
DK25.01.2012
EE25.01.2012
FI25.01.2012
IT25.01.2012
LT25.01.2012
LV25.01.2012
NL25.01.2012
PL25.01.2012
RO25.01.2012
SE25.01.2012
SI25.01.2012
SK25.01.2012
BG25.04.2012
GR26.04.2012
ES06.05.2012
IS25.05.2012
PT25.05.2012
IE17.08.2012
MC31.08.2012
Former [2013/22]AT25.01.2012
BE25.01.2012
CY25.01.2012
CZ25.01.2012
DK25.01.2012
EE25.01.2012
FI25.01.2012
IT25.01.2012
LT25.01.2012
LV25.01.2012
NL25.01.2012
PL25.01.2012
RO25.01.2012
SE25.01.2012
SI25.01.2012
SK25.01.2012
BG25.04.2012
GR26.04.2012
ES06.05.2012
IS25.05.2012
PT25.05.2012
MC31.08.2012
Former [2013/16]AT25.01.2012
BE25.01.2012
CY25.01.2012
CZ25.01.2012
DK25.01.2012
EE25.01.2012
FI25.01.2012
IT25.01.2012
LT25.01.2012
LV25.01.2012
NL25.01.2012
PL25.01.2012
RO25.01.2012
SE25.01.2012
SI25.01.2012
SK25.01.2012
BG25.04.2012
GR26.04.2012
IS25.05.2012
PT25.05.2012
MC31.08.2012
Former [2013/07]AT25.01.2012
BE25.01.2012
CY25.01.2012
CZ25.01.2012
DK25.01.2012
EE25.01.2012
FI25.01.2012
IT25.01.2012
LT25.01.2012
LV25.01.2012
NL25.01.2012
PL25.01.2012
RO25.01.2012
SE25.01.2012
SI25.01.2012
SK25.01.2012
BG25.04.2012
GR26.04.2012
IS25.05.2012
PT25.05.2012
Former [2012/50]BE25.01.2012
CY25.01.2012
CZ25.01.2012
DK25.01.2012
EE25.01.2012
FI25.01.2012
IT25.01.2012
LT25.01.2012
LV25.01.2012
NL25.01.2012
PL25.01.2012
RO25.01.2012
SE25.01.2012
SI25.01.2012
SK25.01.2012
BG25.04.2012
GR26.04.2012
IS25.05.2012
PT25.05.2012
Former [2012/49]BE25.01.2012
CY25.01.2012
CZ25.01.2012
DK25.01.2012
EE25.01.2012
FI25.01.2012
LT25.01.2012
LV25.01.2012
NL25.01.2012
PL25.01.2012
RO25.01.2012
SE25.01.2012
SI25.01.2012
BG25.04.2012
GR26.04.2012
IS25.05.2012
PT25.05.2012
Former [2012/48]BE25.01.2012
CY25.01.2012
EE25.01.2012
FI25.01.2012
LT25.01.2012
LV25.01.2012
NL25.01.2012
PL25.01.2012
SE25.01.2012
BG25.04.2012
GR26.04.2012
IS25.05.2012
PT25.05.2012
Former [2012/41]BE25.01.2012
CY25.01.2012
FI25.01.2012
LT25.01.2012
LV25.01.2012
NL25.01.2012
PL25.01.2012
BG25.04.2012
GR26.04.2012
IS25.05.2012
PT25.05.2012
Former [2012/39]BE25.01.2012
FI25.01.2012
LT25.01.2012
LV25.01.2012
NL25.01.2012
PL25.01.2012
BG25.04.2012
GR26.04.2012
IS25.05.2012
PT25.05.2012
Former [2012/37]BE25.01.2012
FI25.01.2012
LT25.01.2012
NL25.01.2012
PL25.01.2012
BG25.04.2012
GR26.04.2012
IS25.05.2012
PT25.05.2012
Former [2012/36]BE25.01.2012
LT25.01.2012
NL25.01.2012
BG25.04.2012
GR26.04.2012
IS25.05.2012
Former [2012/35]BE25.01.2012
LT25.01.2012
NL25.01.2012
BG25.04.2012
IS25.05.2012
Former [2012/34]BE25.01.2012
LT25.01.2012
IS25.05.2012
Former [2012/33]BE25.01.2012
LT25.01.2012
Cited inInternational search[A]WO02059112  (VERTEX PHARMA [US], et al) [A] 1,19 * page 1, paragraph 2 * * claim 1 *;
 [A]WO02059111  (VERTEX PHARMA [US], et al) [A] 1,19 * page 1, paragraph 2 ** claim 1 *;
 [A]WO02066461  (VERTEX PHARMA [US], et al) [A] 1,19 * page 1, paragraph 2 *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.